Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xiangxue Pharmaceutical Co., Ltd.

Latest From Xiangxue Pharmaceutical Co., Ltd.

Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon

Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.

Deals Business Strategies

Myrexis appoints CEO, CFO and shakes up pipeline

Myrexis, a biotech company developing small molecule compounds with novel chemical structures and distinct mechanisms of action, has decided to keep its interim president and CEO, Robert Lollini, in place as permanent CEO and a member of the board. Mr Lollini was also previously the company's CFO, a role which has now been filled by Andrea Kendell. Mr Lollini joined Myrexis in 2009 from Iomed, and Ms Kendell, who previously served at Moog Medical Devices Group, was most recently Myrexis' vice-president of finance and human resources.

What's Topical? Devices for Transdermal Drug Delivery

The drug delivery device industry is on track to reach almost $23 billion by the year 2011, and the fastest growth will come from the transdermal sector. According to a recent Windhover Information/Medtech Insight report, transdermal delivery technologies will build up to sales of $4.6 billion by 2011. Pharma's increasing fondness for macromolecules will fuel that growth, as will the perennially hot market for transdermal formulations of pain drugs.

BioPharmaceutical Medical Device

Business & Technology Briefs (01/2008)

Brief summaries of recent product and company developments in the device industry, including: developments in continuous glucose monitoring, new liability conerns for device companies, medtech acquisitions in 2007, and the 2008 IPO market.

Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Guangdong Xiangxue Pharmaceuticals
    • Xiangxue Pharmaceutical
    • Guangdong Xiangxue Pharmaceutical Co Ltd
UsernamePublicRestriction

Register